New Alzheimer’s drug targets people with mild cognitive impairment. Here’s what you need to know about the condition

The approval in the United States of a controversial new drug for Alzheimer’s disease, Aduhelm, is shining a spotlight on mild cognitive impairment – problems with memory, attention, language or other cognitive tasks that exceed changes expected with normal ageing.After initially indicating that Aduhelm could be prescribed to anyone with dementia, the US Food and Drug Administration now specifies that the prescription drug be given to individuals with mild cognitive impairment or early-stage…


See also  Meet Rushi Kota, the heartthrob of Netflix’s Never Have I Ever, ABC’s Grey’s Anatomy and Nickelodeon’s iCarly: ‘finally I don’t have to play my skin colour’

Leave a Reply